Latest Financial Position News

Talonx Resources (ASX: TXR) reported robust drilling results at its Viking and Blair North gold projects, highlighting a high-grade shallow oxide gold zone at Viking’s Beaker 2 prospect. The company also advanced exploration and licence renewal efforts at its Kihabe zinc-lead-silver project in Botswana, closing the quarter with $0.72 million cash.

Swift TV Limited has completed its transition from development to commercial rollout, securing Google certification and Netflix approval while expanding contracts across aged care, hospitality, and workforce accommodation.

Finder Energy has secured key regulatory approval for its KTJ Project in Timor-Leste and raised $27 million to advance development, positioning for a Final Investment Decision in Q3 2026.

Galilee Energy has commenced drilling its Zydeco-1 well in Louisiana, executing a cost-optimised plan targeting up to 13.7 billion cubic feet of gas and 610,000 barrels of condensate, marking a key milestone in its US Gulf Coast expansion.

Everest Metals has reported strong progress across its Western Australian projects, including maiden and upgraded resource estimates at Revere, Mt Edon, and Mt Dimer, alongside advancing mining and proprietary processing technology.

Great Divide Mining Ltd has marked a key milestone by starting gold production and dispatching concentrate shipments from its Challenger Gold Mine, while advancing exploration at Coonambula.

Far East Gold has boosted its stake in the Idenburg Gold Project to 51%, revealing a 44% increase in inferred gold resources to 780,000 ounces. The company’s Independent Board Committee advises shareholders to reject an unsolicited takeover bid from Xingye Gold, which an expert deems undervalues the company.

Talga Group has marked a milestone with its first commercial delivery of natural graphite anode outside Asia, progressing key funding discussions and strategic partnerships to support its Vittangi Anode Project.

Tennant Minerals has confirmed robust high-grade copper-gold-bismuth mineralisation at its Bluebird discovery, extending the resource down-plunge and westward. The company secured $2.8 million in funding to accelerate drilling and development.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.